Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | FLT4 | P35916 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | CAMK1 | Q14012 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | SGK2 | Q9HBY8 | 2/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477840 | 0.86 | CDK5 (0.45) | PLK4AURKACHEK2CDK1CDK2 | |
| SCHEMBL477755 | 0.84 | JUN (0.64) | PLK4AURKACHEK2CDK1CDK2 | |
| SCHEMBL944523 | 0.83 | ABL1 (0.42) | PLK4AURKACHEK2CDK1CDK2 | |
| SCHEMBL477936 | 0.78 | ALDH1A1 (0.46) | PLK4AURKACHEK2CDK1CDK2 | |
| SCHEMBL9178423 | 0.77 | HTR2A (0.54) | JUNNFKB1NFKB2RELACES1 | |
| SCHEMBL477987 | 0.76 | JUN (0.52) | PLK4AURKACHEK2CDK1CDK2 | |
| SCHEMBL172370 | 0.74 | LMNA (0.58) | CES1CHEK1TGM2PPOXLMNA | |
| SCHEMBL11505743 | 0.71 | CES1 (0.45) | JUNNFKB1NFKB2RELACES1 | |
| SCHEMBL31098212 | 0.69 | CES1 (0.45) | KDRJUNNFKB1NFKB2RELA | |
| SCHEMBL9180628 | 0.69 | CHEK1 (0.43) | JUNNFKB1NFKB2RELACES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994160-B2 | Pyridazine compounds as glycogen synthase kinase 3 inhibitors | ABBOTT GMBH & CO. KG (DE) | 2011-08-09 | — | — | US | claimed |
| US-20090325937-A1 | Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors | ABBOTT GMBH & CO. KG (DE) | 2009-12-31 | — | — | US | claimed |
| EP-1902055-A1 | PYRIDAZINE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | Abbott GmbH & Co. KG (DE) | 2008-03-26 | — | — | EP | claimed |
| WO-2007006566-A1 | PYRIDAZINE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2007-01-18 | — | — | WO | claimed |
| US-9856234-B2 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-02 | — | — | US | disclosed |
| EP-2411379-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2014-12-17 | — | — | EP | disclosed |
| US-20140148458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | disclosed |
| US-8642598-B2 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | ABBVIE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2091943-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2013-11-20 | — | — | EP | disclosed |
| US-8455648-B2 | 1-(7-(hexahydropyrrolo [3,4-c] pyrrol-2 (1H)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3) | ABBOTT GMBH & CO. KG (DE) | 2013-06-04 | — | — | US | disclosed |
| EP-2297154-B1 | 1- (7-(HEXAHYDROPYRROLO [3, 4-C]PYRROL-2 (1H) -YL) QUIN0LIN-4-YL) -3- (PYRAZIN-2-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK-3) INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2013-04-03 | — | — | EP | disclosed |
| EP-2535336-A1 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | Abbott GmbH & Co. KG (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20100324042-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBOTT GMBH & CO. KG. (DE) | 2010-12-23 | — | — | US | disclosed |
| WO-2010109005-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-09-30 | — | — | WO | disclosed |
| US-20090325937-A1 | Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors | ABBOTT GMBH & CO. KG (DE) | 2009-12-31 | — | — | US | disclosed |
| WO-2009130317-A1 | 1- (7-(HEXAHYDROPYRROLO [3, 4-C] PYRROL-2 (1H) -YL) QUIN0LIN-4-YL) -3- (PYRAZIN-2-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK-3) | ABBOTT GMBH & CO. KG (DE) | 2009-10-29 | — | — | WO | disclosed |
| EP-2091943-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | Abbott GmbH & Co. KG (DE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008046919-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2008-04-24 | — | — | WO | disclosed |
| EP-1902055-A1 | PYRIDAZINE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | Abbott GmbH & Co. KG (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007006566-A1 | PYRIDAZINE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325937-A1 | Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors | GSK3B, GSK3A, GYS2 | PLK4 39/4885AURKA 337/4885CHEK2 104/4885 |
| US-20140148458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | GSK3B, GSK3A, GYS2 | PLK4 82/4885AURKA 332/4885CHEK2 228/4885 |
| US-20100324042-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | GSK3B, GSK3A, GYS2 | PLK4 82/4885AURKA 332/4885CHEK2 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.